SYGNIS Reports Financial Results For The Second Quarter And First Six Months Of 2017 Post author:Sam Post published:August 2, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Biogen and AbbVie Voluntarily Pull Multiple Sclerosis Drug Off the Market March 1, 2018 Glaukos Completes Patient Enrollment In Pivotal Phase Of U.S. IDE Clinical Trial For iStent SUPRA February 15, 2017 Karolinska Development AB Release: Pharma Portfolio Company Announces FDA 510(K) Clearance For Marketing Of OSSDSIGN Cranial For Sale In The U.S.A. January 19, 2017
Glaukos Completes Patient Enrollment In Pivotal Phase Of U.S. IDE Clinical Trial For iStent SUPRA February 15, 2017
Karolinska Development AB Release: Pharma Portfolio Company Announces FDA 510(K) Clearance For Marketing Of OSSDSIGN Cranial For Sale In The U.S.A. January 19, 2017